Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Perspective
  • Published:

Translational Therapeutics

Cell proliferation, drug distribution and therapeutic effects in relation to the vascular system of solid tumours

British Journal of Cancer volume 128, pages 413–418 (2023)Cite this article

Subjects

Abstract

In this perspective, the authors summarise some properties of the solid tumour micro-environment that have been explored during the last 55 years. It is well established that the concentrations of nutrients, including oxygen, decrease with increasing distance from tumour blood vessels, and that low extracellular pH is found in nutrient-poor regions. Cell proliferation is dependent on nutrient metabolites and decreases in regions distal from patent blood vessels. Proliferating cells cause migration of neighbouring cells further from blood vessels where they may die, and their breakdown products pass into regions of necrosis. Anticancer drugs reach solid tumours via the vascular system and establish concentration gradients such that drug concentration within tumours may be quite variable. Treatment with chemotherapy such as doxorubicin or docetaxel can kill well-nourished proliferating cells close to blood vessels, thereby interrupting migration toward necrotic regions and lead to re-oxygenation and renewed proliferation of distal cells, as can occur with radiotherapy. This effect leads to the paradox that cancer treatment can rescue cells that were destined to die in the untreated tumour. Renewed and sometimes accelerated repopulation of surviving tumour cells can counter the effects of cell killing from repeated treatments, leading to tumour shrinkage and regrowth without changes in the intrinsic sensitivity of cells to the administered treatment. Strategies to prevent these effects include the combined use of chemotherapy with agents that selectively kill hypoxic tumour cells, including inhibitors of autophagy, since this is a process that may allow recycling of cellular macromolecules from dying cells and improve their survival.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Schematic representation of a functional blood vessel and its surrounding cells.
Fig. 2: Distribution of doxorubicin in solid tumours.
Fig. 3: Time-dependent changes in hypoxic cells, and in their proliferation, in doxorubicin-treated and control mice bearing MCF-7 xenografts.
Fig. 4: Schematic diagram to illustrate how accelerating repopulation of tumours (that may occur with improving nutrition) can overcome the killing effects of repeated doses of drugs or radiation.
Fig. 5: Inhibition of Autophagy can increase the effectiveness of anticancer drugs.

Similar content being viewed by others

References

  1. Steel GG, Lamerton LF. The growth rate of human tumours. Br J Cancer. 1966;20:74–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Steel GG. Cell loss as a factor in the growth rate of human tumours. Eur J Cancer. 1967;3:381–7.

    Article  CAS  Google Scholar 

  3. Goldacre RJ, Sylven B. On the access of blood-borne dyes to various tumour regions. Br J Cancer. 1962;16:306–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8:519–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer. 1955;9:539–49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Tannock IF. The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour. Br J Cancer. 1968;22:258–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989;49:6449–65.

    CAS  PubMed  Google Scholar 

  8. Helmlinger G, Yuan F, Dellian M, Jain RK. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med. 1997;3:177–82.

    Article  CAS  PubMed  Google Scholar 

  9. Chaplin DJ, Durand RE, Olive PL. Cell selection from a murine tumour using the fluorescent probe Hoechst 33342. Br J Cancer. 1985;51:569–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Tan Q, Saggar JK, Yu M, Wang M, Tannock IF. Mechanisms of drug resistance related to the microenvironment of solid tumors and possible strategies to inhibit them. Cancer J. 2015;21:254–62.

    Article  CAS  PubMed  Google Scholar 

  11. Begg AC, Denekamp J, Howes AE. Re-oxygenation of tumours after irradiation and cell population kinetics. J Physiol. 1969;202:16P–17P.

    CAS  PubMed  Google Scholar 

  12. Kallman RF. Reoxygenation and repopulation in irradiated tumors. Front Radiat Ther Oncol. 1988;22:30–49.

    Article  CAS  PubMed  Google Scholar 

  13. Speke AK, Hill RP. The effects of clamping and reoxygenation on repopulation during fractionated irradiation. Int J Radiat Oncol Biol Phys. 1995;31:857–63.

    Article  CAS  PubMed  Google Scholar 

  14. Tannock I, Howes A. The response of viable tumor cords to a single dose of radiation. Radiat Res. 1973;55:477–86.

    Article  CAS  PubMed  Google Scholar 

  15. Lankelma J, Dekker H, Luque FR, Luykx S, Hoekman K, van der Valk P, et al. Doxorubicin gradients in human breast cancer. Clin Cancer Res. 1999;5:1703–7.

    CAS  PubMed  Google Scholar 

  16. Primeau AJ, Rendon A, Hedley D, Lilge L, Tannock IF. The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res. 2005;15:8782–8.

    Article  Google Scholar 

  17. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006;6:583–92.

    Article  CAS  PubMed  Google Scholar 

  18. Saggar JK, Tannock IF. Chemotherapy rescues hypoxic tumor cells and induces their reoxygenation and repopulation—an effect that is inhibited by the hypoxia-activated prodrug TH-302. Clin Cancer Res. 2015;21:2107–14.

    Article  CAS  PubMed  Google Scholar 

  19. Klement RJ, Champ CE. Calories, carbohydrates, and cancer therapy with radiation: exploiting the five R’s through dietary manipulation. Cancer Metastasis Rev. 2014;33:217–29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Tannock IF. The five Rs of chemotherapy. Lancet Oncol. 2016;17:703–5.

    Article  PubMed  Google Scholar 

  21. Davis AJ, Tannock JF. Repopulation of tumour cells between cycles of chemotherapy: a neglected factor. Lancet Oncol. 2000;1:86–93.

    Article  CAS  PubMed  Google Scholar 

  22. Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer. 2005;5:516–25.

    Article  CAS  PubMed  Google Scholar 

  23. Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988;27:131–46.

    Article  CAS  PubMed  Google Scholar 

  24. Brade AM, Tannock IF. Scheduling of radiation and chemotherapy for limited-stage small-cell lung cancer: repopulation as a cause of treatment failure? J Clin Oncol. 2006;24:1020–2.

    Article  PubMed  Google Scholar 

  25. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004;4:437–47.

    Article  CAS  PubMed  Google Scholar 

  26. Dorie MJ, Brown JM. Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine. Cancer Chemother Pharm. 1997;39:361–6.

    Article  CAS  Google Scholar 

  27. Saggar JK, Tannock IF. Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy. Int J Cancer. 2014;134:2726–34.

    Article  CAS  PubMed  Google Scholar 

  28. Sun JD, Liu Q, Ahluwalia D, Li W, Meng F, Wang Y, et al. Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer. Cancer Biol Ther. 2015;16:438–49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Williamson SK, Crowley JJ, Lara PN Jr, McCoy J, Lau DHM, Tucker RW, et al. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol. 2005;23:9097–104.

    Article  CAS  PubMed  Google Scholar 

  30. DiSilvestro PA, Ali S, Craighead PS, Lucci JA, Lee Y-C, Cohn DE, et al. Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study. J Clin Oncol. 2014;32:458–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Van Cutsem E, Lenz H-J, Furuse J, Tabernero J, Heinemann V, Ioka, T, et al. MAESTRO: a randomized, double-blind phase III study of evofosfamide in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma. J Clin Oncol. 2016;34(Suppl):Abstract 4007.

  32. Tap WD, Papai Z, Van Tine BA, Attia S, Ganjoo KN, Jones RL, et al. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2017;18:1089–103.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Hunter FW, Wouters BG, Wilson WR. Hypoxia-activated prodrugs: paths forward in the era of personalised medicine. Br J Cancer. 2016;114:1071–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Rouschop KM, van den Beucken T, Dubois L, Niessen H, Bussink J, Savelkouls K, et al. The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. J Clin Invest. 2010;120:127–41.

    Article  CAS  PubMed  Google Scholar 

  35. Tan Q, Wang M, Yu M, Zhang J, Bristow RG, Hill RP, et al. Role of autophagy as a survival mechanism for hypoxic cells in tumors. Neoplasia. 2016;18:347–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Tan Q, Joshua AM, Wang M, Bristow RG, Wouters BG, Allen CJ, et al. Up-regulation of autophagy is a mechanism of resistance to chemotherapy and can be inhibited by pantoprazole to increase drug sensitivity. Cancer Chemother Pharm. 2017;79:959–69.

    Article  CAS  Google Scholar 

  37. Tan Q, Joshua AM, Saggar JK, Yu M, Wang M, Kanga N, et al. Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy. Br J Cancer. 2015;112:832–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Emeritus Professor of Medical Oncology, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON, M5G 2M9, Canada

    Ian F. Tannock

  2. Emeritus Professor of Radiation Biology at the Institute of Cancer Research, London, UK

    G. Gordon Steel

Authors
  1. Ian F. Tannock
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Gordon Steel
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Both authors contributed to the writing of the MS.

Corresponding author

Correspondence to Ian F. Tannock.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics approval and consent to participate

Not applicable.

Consent to publish

Not applicable.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tannock, I.F., Gordon Steel, G. Cell proliferation, drug distribution and therapeutic effects in relation to the vascular system of solid tumours. Br J Cancer 128, 413–418 (2023). https://doi.org/10.1038/s41416-022-02109-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41416-022-02109-6

Search

Advanced search

Quick links